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Abstract Forkhead box protein 3 (Foxp3) is known as a
specific marker for regulatory T cells which contribute to
immunosuppression in tumor microenvironment. However,
existing studies regarding clinical significance of Foxp3?
tumor-infiltrating lymphocytes (TILs) in glioblastoma
(GBM) remained discrepant. In this study, we aimed to
explore whether this subtype of TILs correlated with prog-
nosis in patients with GBM. Foxp3? TILs as well as CD8?
ones were detected by immunohistochemistry on paraffin-
embedded tumor samples from 62 patients. Staining for p53,
MGMT and Ki-67 were also performed. The correlation of
TIL subtypes with clinicopathologic features were analyzed.
Progression-free survival (PFS) and overall survival (OS)
were estimated by Kaplan–Meier method and compared
using log-rank test. Independent prognostic factors for PFS
and OS were determined through univariate and multivari-
ate analysis. Significant correlation was found between
Foxp3 and CD8 expression (P = 0.003), but not between
TIL subtypes and clinicopathologic characteristics. Patients
with higher density of Foxp3? TILs showed relatively
shorter PFS (P \ 0.001) and OS (P = 0.003) whereas
patients with higher density of CD8? TILs obtained no
significant differences in survival. Survival analysis based
on molecular classifications further clarified these predictive
values. Univariate and multivariate analysis revealed that
frequency of Foxp3? TILs was probably associated with
both PFS (P = 0.002) and OS (P = 0.003). In conclusion,
the results suggest that Foxp3 positive infiltrates could
provide an independent predictive factor in GBM.
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Introduction
Glioma is one of the most prevalent tumors in central nervous
system and accounts for more than 50 % of primary intracranial
neoplasms in adults. Given that combination of surgery,
radiotherapy and chemotherapy has made rapid advances in
recent years, the median survival of glioblastoma (GBM, WHO
grade IV glioma) remains at 14.6 months and 2-year survival
rate is only 26.5 % [1]. It has been realized by more and more
researchers that a final cure of this malignancy may depend on
better understanding of the biological behavior [2]. For this,
diverse theories are emerging to explain GBM’s malignant
characteristics, among which the mechanism of immune escape
seems extremely prospective and attracts widely attentions.
Since the brain was not regarded as an immunoprivi-
leged organ, various subtypes and immunologic features of
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tumor infiltrating lymphocytes (TILs) have been investi-
gated over the past decade [3]. Besides well-known CD8?
and CD4? T cells, regulatory T cells (Tregs), initially
recognized by CD4? CD25? profile, are also considered
to play an important part in suppressing immune response
and promoting tumor invasion [4, 5]. Many studies have
revealed Tregs’ upregulation in peripheral blood of patients
suffering from liver, gastric, breast and esophagus cancer,
as well as infiltration in tumor microenvironment [6–8].
Forkhead box protein 3 (Foxp3), primarily identified as a
transcription factor for Treg, is likely to be responsible for
its immunosuppressive function and has popularly become
its single marker in cancer research [9]. To evaluate Tregs’
prognostic value, research on the correlation between the
density of Foxp3? TILs in tumor tissue and clinical out-
come was performed in nearly all kinds of tumors, leading
to both positive and negative results [10]. As for GBM, the
discrepancy also exists that two early studies denied
Foxp3? TILs’ association with prognosis whereas a recent
study demonstrated patients with higher Foxp3 expression
had shorter survival time than those with lower expression
[11–13]. Hence, existing data are still limited and more
obtained from larger number of cases are still in need for
further elucidating whether Foxp3? TILs can be used as a
prognostic factor for GBM patients. In addition, the rela-
tionship between Foxp3 and other GBM molecular markers
such as p53, MGMT, Ki-67 is also unclear.
Our early research has focused on the interaction
between glioma stem-like cells (GSCs) and microglias/
macrophages through negative costimulatory molecules
such as B7 family, and revealed potential mechanism
underlying GBM’s immune escape induced by GSCs [14,
15]. Based on these, we now push our study forward to the
TIL-centered downstream of the mechanism, by exploring
the immunosuppressive Foxp3? TILs at first. Here we
detected the expression of Foxp3 in tumor tissues obtained
from 62 GBM patients and examined its predictive sig-
nificance for clinical outcome.
Materials and methods
Patients and tissue samples
From 2006 to 2010, all newly diagnosed GBM patients
who underwent tumor resection at Huashan Hospital by
one neurosurgical team were enrolled in our study. Histo-
pathological diagnosis was performed by experienced
neuropathologists according to World Health Organization
(WHO) guidelines [16]. All patients received radiotherapy
(fractionated focal irradiation 2 Gy/day, 5 days/week for
6 weeks, 60 Gy totally) and temozolomide therapy
(75 mg/m2 day, 7 days/week throughout radiotherapy,
followed by 150–200 mg/m2 for 5 days during each cycle,
28 days per cycle for 6 cycles) postoperatively. Informed
consent was obtained from all patients and the protocol for
this study was approved by the Institutional Review Board
of Huashan Hospital.
Detailed clinicopathologic data during hospitalization
were collected from medical records for each patient,
including sex, age, tumor location, tumor diameter and the
extent of tumor resection. Follow up was completed at
August, 2012, collecting information about following treat-
ments, recurrence and survival status. Progression-free sur-
vival (PFS) was defined as the time interval from diagnosis to
first tumor progression or recurrence. Overall survival (OS)
was measured from diagnosis to death or censor.
Immunohistochemical staining
Paraffin sections (4 lm) of GBM were mounted on silan-
ized slides, dewaxed at 56 C for 30 min, deparaffinized
with xylenes and rehydrated through ethanol. Peroxidase
activity was quenched with 3 % hydrogen peroxidase for
15 min and non-specific background staining was elimi-
nated by blocking buffer (2 % goat serum, 0.2 % Triton
X-100, 0.1 % bovine serum albumin in phosphate-buffered
saline) at room temperature for 1 h. Primary antibodies
against Foxp3 (1:50; Abcam), CD8 (prediluted; Dako), p53
(1:400; Abcam), MGMT (1:100; Abcam) and Ki-67 (1:50;
Abcam) were then applied overnight at 4 C. After a series
of washing, immunodetection was performed using labeled
polymer horseradish peroxidase mouse antibody (EnVi-
sion? system, Dako). Slides were subsequently rinsed with
deionized water, visualized with 3,30-diaminobenzidine for
10 min and counterstained with Mayers hematoxylin. The
negative controls were obtained by omitting primary anti-
bodies. Human lymph nodes were used as a positive con-
trol for Foxp3, CD8, MGMT and Ki-67, while human
gastric adenocarcinoma tissue was chosen for p53.
Evaluation of immunohistochemical variables
Slides were reviewed under Nikon eclipse TE2000-S
microscope by two independent observers (Y. W. and Q.
Y.) blind to clinical outcomes and captured using Image-
Pro Plus 5.0 software. For detection of CD8 expression,
lymphocytes with clear membranous staining were regar-
ded as positive ones. As to Foxp3 analysis, lymphocytes
which showed evident nuclear staining were interpreted as
immunoreactive cells. The numbers of CD8? and Foxp3?
cells were counted under 5 randomly selected fields at high
magnification (9400) by each observer. With an eyepiece
grid covering 0.24 mm2, positively stained lymphocytes
were finally expressed as cell numbers per mm2 of tumor
tissue [17].
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Labeling index, which meant the percentage of nuclear
positive cells under high-powered field (HPF), was applied
to evaluate expression patterns of p53 [18], MGMT [19]
and Ki-67 [20]. The cutoff values were 5 % for p53, 10 %
for MGMT and 20 % for Ki-67, respectively. Cases with
labeling index above cutoff value were categorized under
positive groups.
Statistical analysis
All data analysis except Cox regression models was per-
formed with GraphPad Prism 5.0 software. Clinicopatho-
logic parameters were treated as discrete variables and the
TIL distributions were compared using the Mann–Whitney
U-test. Survival analysis was performed with the Kaplan–
Meier method and significance was confirmed by the log-
rank test. Cox proportional hazards regression models were
constructed in both univariate and multivariate analysis by
SPSS 20.0 software. Statistical significance was established
at P \ 0.05.
Results
Clinicopathologic data of the patients
Forty-three male and nineteen female patients were
enrolled in this study, and the median age was 56 years old
(range 13–77). The tumors were located in various regions
and gross total resection was achieved in 50 patients.
According to our categorization, more than one-third of the
patients were positive for p53, MGMT or Ki-67. The
median follow-up duration was 17.5 months (range 3–77)
and no patient was lost. At the last follow-up, only four
were still alive and two of them had experienced tumor
recurrence.
Correlation of TIL parameters with clinicopathologic
characteristics
Different intensities of Foxp3 and CD8 expression were
shown in Fig. 1. The density of Foxp3? TILs was statis-
tically lower than that of CD8? ones (8.6 vs 49.6 mm2,
P \ 0.001). As the two parameters were significantly
correlated (Supplementary Fig. 1), we set the Foxp3?/
CD8? ratio (Foxp3? cell count divided by CD8? cell
count) as a new parameter for later analysis.
To evaluate the impact of baseline factors on TILs’
distribution, we then analyzed the correlation between
parameters of TILs and clinicopathologic characteristics
(Table 1). Significance was only found between MGMT
status and CD8? TILs’ density, where cases with positive
MGMT status showed much more CD8? cells’ infiltration.
Although significance was not reached, higher expression
of Ki-67 provided possible association with the decreased
number of Foxp3? TILs. Other correlations with differ-
ences approaching significance existed between extent of
resection and CD8? TILs, sex and Foxp3?/CD8? ratio.
Survival analysis based on TIL parameters
To elucidate the prognostic effect of TIL parameters, we
next dichotomized the patients into two groups using the
median density as cutoff value. The median PFS was
9 months in patients with higher Foxp3 expression and
12 months in patients with lower Foxp3 expression. The
difference between the two groups was significant (Fig. 2a)
and OS analysis showed similar results (Fig. 2b). Com-
paring the two groups categorized by CD8 expression,
significant difference was reached for neither PFS nor OS
(Fig. 2c, d).
Considering the inherent molecular heterogeneity within
GBM, we sought to analyze the prognostic significance of
TIL parameters based on different molecular markers
(Table 2). Higher density of Foxp3? TILs was correlated
with shortened PFS and OS regardless of MGMT status.
But for Ki-67, this correlation was only valid in negative
groups. CD8 expression still did not predict patient out-
come in these subgroups.
Prognostic significance of variables
In order to identify independent prognostic factors for
patient survival, we investigated clinicopathologic charac-
teristics as well as parameters of TILs in Cox proportional
hazards regression models (Table 3). Univariate analysis
was first performed and PFS was significantly different
according to Foxp3? TIL density, Foxp3?/CD8? ratio
and extent of resection. These factors together with age and
tumor diameter, which gained the two least P values in the
rest, were then adopted in model A for multivariate ana-
lysis. This model revealed that extent of resection, Foxp3?
TIL density and tumor diameter were the strongest prog-
nostic factors. Thereafter, a second model (B) was adjusted
only for the three variances and found that tumor diameter
no longer showed independent prognostic value for PFS.
Univariate analysis of OS indicated that Foxp3? TIL
density and extent of resection significantly coincided with
patient outcome whereas no correlation was established for
others. To perform multivariate analysis of OS, models
were developed in the same way as described above.
Foxp3? TIL density, extent of resection and Ki-67 status
were adopted in model B and all inferred as independent
prognostic factors for patient OS.
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Discussion
Recently emerging articles have investigated the correla-
tion between tumor-infiltrating Foxp3? cells and clinical
prognosis in various kinds of tumors, indicating discrepant
results on how these TILs really predict patient outcome.
To settle this controversy, DeLeeuw et al. [10] made great
efforts in meta-analyzing the prognostic significance of
Foxp3? TILs across 16 non-lymphoid cancers by enrolling
58 studies. Assessing several technical and biologic factors,
they finally proved two causes, tumor site and use of
multiple markers, responsible for these debatable claims.
Accordingly, Foxp3? TILs coincided with generally
favorable prognosis in colorectal cancer but poor prognosis
in hepatocellular cancer. However, studies concerning
glioma or even GBM were really rare and not included in
the systematic review.
In 2008, Heimberger et al. [11] for the first time ana-
lyzed prognostic impact of Foxp3? TILs in human glioma
based on immunohistochemical staining and reached no
statistical significance between 25 patients with Foxp3
presence and 27 ones with Foxp3 absence. This conclusion
was later confirmed by Jacobs et al. [12] using flow
cytometry. Nevertheless, the second study only enrolled 29
GBM patients and the comparison performed by log-rank
test showed marginal significance (P = 0.06). Alterna-
tively, Wiencke et al. [21] revealed that patients with low
Foxp3 expression gained a significantly prolonged survival
by quantitative methylation specific PCR, and it was lately
confirmed by Wang et al. [13] on immunohistochemistry.
Fig. 1 Representative micrographs of Foxp3 and CD8 expression in GBM. Low (a), high (b) numbers of Foxp3? cells with nuclear stain and
low (c), high (d) numbers of CD8? cells with membrane stain were shown respectively. Scale bars 50 lm
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Moreover, Fong et al. [22] from U.S. suggested that in
patients who received DC vaccination, decreased fre-
quencies of Tregs after the treatment predicted extended
survival.
Our study in this article had the largest population to
date and suggested that Foxp3 might be an independent
adverse prognostic factor. The controversy among these
studies may be explained as follows. First, various methods
to identify Tregs, including flowcytometry and immuno-
histochemistry, may lead to different results. Generally,
flowcytometry was more accurate in determining whether
the Foxp3? cells were really Tregs by using multiple
staining. However, staining strategy also varied between
studies performing flowcytometry that Heimberger et al.
defined CD4? CD25? Foxp3highCD127low cells as Tregs
while Fong et al. detected CD3? CD4? CD25? CD127low
ones. Second, cutoff values were different among these
studies. For example, Heimberger, et al. used the presence/
absence of Foxp3? TILs to determine the clinical signifi-
cance, but our study dichotomized patients by the median
of Foxp3 density. More complicated methods such as
recursive partitioning survival tree were performed by
Fong et al. Therefore, to make a more convincible com-
parison between different studies, an accurate and reason-
able cutoff value should be developed and widely accepted
in the future. Third, the populations enrolled in these
studies were obviously heterogeneous. Subtypes of GBM,
anti-tumor treatment or even race, which usually influenced
patient outcome, were not unified, thus increasing inter-
study bias. In addition, other technical details should never
be ignored, encompassing the antibodies used, evaluation
strategy and statistical analysis.
CD8? TILs, also known as cytotoxic T lymphocytes
(CTL), have long been believed to take a major part in
adaptive immunity against tumor invasion, thus theoreti-
cally prolonging patient survival and having great potential
as a prognostic indicator. In support, both Yang et al. [23]
and Kim et al. [24] found a better outcome in GBM
patients with higher CD8? cells infiltration. Intriguingly,
many studies contradicted the hypothesis and showed no
Table 1 Correlation of
clinicopathologic characteristics
with TIL parameters
Number Foxp3? CD8? Foxp3?/CD8?
Mean P Mean P Mean P
Sex
Male 43 7.72 0.448 47.39 0.432 0.304 0.086
Female 19 10.77 54.67 0.638
Age (years)
C55 29 10.82 0.681 51.21 0.893 0.593 0.783
\55 33 6.76 48.23 0.242
Location
Frontal 23 10.53 0.658 58.50 0.626 0.222 0.429
Parietal 4 2.81 50.31 0.067
Temporal 15 8.83 39.33 0.936
Other site 7 5.59 50.95 0.195
Combined 13 8.59 44.87 0.340
Diameter (cm)
C4 31 7.72 0.740 51.12 0.725 0.205 0.745
\4 31 9.60 48.13 0.609
Resection
GTR 50 8.27 0.655 54.58 0.063 0.241 0.201
Non-GTR 12 10.28 28.96 1.098
p53
Positive 29 9.99 0.420 56.05 0.182 0.238 0.640
Negative 33 7.49 43.98 0.555
MGMT
Positive 22 8.54 0.525 69.53 0.009 0.215 0.971
Negative 40 8.72 38.68 0.512
Ki-67
Positive 23 4.76 0.058 38.06 0.374 0.204 0.106
Negative 39 10.95 56.44 0.526
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relationship between CD8? TILs and clinical outcome [25,
26]. It was even reported by Wiencke et al. [21] that more
CD3? TILs in GBM tissues, most of which were CD8?,
predicted poorer prognosis. In accordance, there remained
no significant difference in our study when comparing PFS
or OS according to CD8 dichotomization. These findings
together indicated that different activation modes of CD8?
TILs might coexist and were not distinguished by immu-
nohistochemical staining. Furthermore, as a positive cor-
relation was discovered between Foxp3 and CD8
expression in some studies [17, 27], CD8? TILs’ interac-
tions with inhibitory T cells as well as other immune par-
ticipators such as microglias/macrophages should be taken
into account. In support, it was reported that Tregs could
compromise CTLs’ function via immunosuppressive
cytokines such as IL-4, TGF-b or direct cell to cell contact
[28]. Our results that the density of Foxp3 instead of CD8
was perhaps significant for survival may imply that sup-
pressive capacity of Tregs was sufficient to override the
anti-tumor immune response initiated by CD8? TILs in
GBM microenvironment. So further investigation of the
crosstalk between Tregs and CD8? TILs will pave the way
for developing effective immunotherapy to inhibit glioma
propagation.
Integrating both subtypes and probably reflecting more
comprehensive immune pattern, the ratios such as Foxp3?/
CD8? were frequently chosen as candidates for indepen-
dent prognostic factors and led to positive findings in
Fig. 2 Kaplan–Meier survival curves and log-rank tests for Foxp3
and CD8 in GBM patients. a Higher level of Foxp3? TIL density
correlated significantly with shorter PFS. b Higher level of Foxp3?
TIL density correlated significantly with shorter OS. c PFS was not
significantly different for patients with high or low level of CD8?
TIL density. d OS was not significantly different for patients with
high or low level of CD8? TIL density
Table 2 Prognostic significance of TIL parameters in molecular
subtypes
Foxp3 CD8
PFS OS PFS OS
p53
Positive 0.065 0.030 0.330 0.196
Negative 0.004 0.058 0.745 0.486
MGMT
Positive 0.013 0.028 0.914 0.443
Negative 0.014 0.023 0.579 0.966
Ki-67
Positive 0.649 0.570 0.597 0.414
Negative 0.000 0.021 0.402 0.254
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several cancers. It was reported that the ratio of regulatory
and cytotoxic T cells rather than their absolute numbers
had greater impact on tumor growth in hepatocellular
carcinoma [29]. Higher CD8?/Foxp3? was authenticated
to be associated with favorable outcome in both breast
cancer and ovarian cancer [25, 30]. Partially supporting
these results, we also found that higher Foxp3?/CD8?
was likely to predict shorter PFS in GBM patients but
when adjusted by other factors, it was no longer signifi-
cant. Moreover, neither univariate nor multivariate ana-
lysis suggested the ratio as prognosis factor for OS. The
positive correlation between expression of Foxp3 and CD8
might compromise their ratio’s prognostic value compared
with single Foxp3. Still and all, the ratio of subtypes
should be included in future research allowing for its
potential effect.
Instead of a single entity, cancer is a heterogenous
disease with different profiles of genetic and epigenetic
alterations, which may influence immune cells’ behavior in
interdisciplinary microenvironment and thus prognostica-
tion [31]. In support, Frey et al. [32] identified frequency
of Foxp3? TILs as an independent prognostic factor in
mismatch repair-proficient colorectal cancer other than
mismatch repair-deficient colorectal cancer. Additionally,
intratumoral Tregs were demonstrated to predict worse OS
in cyclooxygenase-2-positive uveal melanoma while the
relationship between Foxp3? cells and clinical outcome
has been tested repeatedly in breast cancer subtypes
according to estrogen receptor [25, 33, 34]. Our research
was the first to explore Foxp3? TILs’ prognostication
based on molecular classifications in GBM and selected
common biomarkers such as p53, MGMT and Ki-67 for
analysis. Of note, we found that Foxp3 could show
stronger prognostic significance in Ki-67- group com-
pared with Ki-67? group, and elucidation of the under-
lying mechanisms relies on further experiments targeting
at cross-talk among these molecular.
There are some limitations of this study. First, although
bigger than previous ones, our study sample was still
limited to obtain enough differences between groups,
which might partially explain that only Foxp3 density and
extent of resection were identified as potential prognostic
factors for PFS and OS. Second, since it has been recently
reported that glioma cells also expressed Foxp3, our data
based on immunohistochemistry were prone to interpreting
the biologic behavior of Foxp3 expression more than exact
TILs. For this, double or multiple staining plus specific
markers such as CD4 and CD25 will be needed in later
investigation. Third, we only detected Foxp3? and CD8?
cells but as there existed complicated interactions among
various immune cells in tumor microenvironment, it would
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In conclusion, the present study observes poorer survival
in GBM patients with more Foxp3? TILs, and indicates
the density of Foxp3? TILs as a possible prognostic factor
via multivariate models. Furthermore, our results suggest
that evaluation of Foxp3? TILs in combination with var-
ious molecular classifications might improve the prognos-
tic stratification of GBM. Allowing for several limitations,
larger studies are still needed in the future to provide
stronger evidence for utilizing Foxp3 as a candidate bio-
marker or even implementing Foxp3? TILs as novel target
of immunotherapy.
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